

Julius Bär

BIOTECH – A TECHNICAL BUY OPPORTUNITY


Julius Baer Structured Products
April 2016



WHY INVEST IN THE BIOTECH SECTOR

Tracker Certificate on the US Biotech Basket

- The biotech sector represents a **technical buy opportunity**:
 - In March 2016 92% of all S&P 500 stocks traded above their 50-day moving average
 - This is the best reading since 2013 and indicates that investors are buying stocks on a broad basis
 - **JB Technical Research recommends adding exposure to selected biotech stocks**
- JB Global Healthcare Research believes that biotech valuations had become oversold. It may take a long time for biotech share prices to return to their previous highs, but the environment for the remainder of the year should be stable-to positive
- If you share this view then the **Tracker Certificate on the US Biotech Basket** provides selective exposure to 10 equally weighted healthcare stocks (5 BUY, 5 HOLD rated by JB Research)



INDICATIVE TERMS*

Tracker Certificate on the US Biotech Basket

Issuer	Bank Julius Baer & Co. Ltd., Guernsey Branch (Rating: Moody's A2)
Currency	USD
Maturity	1 year
Underlying	US Biotech Basket (10 shares, equally weighted)
Dividends	Discounted
Participation	100%
Settlement type	Cash settlement
Initial value	USD 100
Issue price	USD 101.10
Valor / ISIN / Symbol	30.689.212 / CH03068 92123/ JFQCN
Subscription period	Until 29 April 2016, 12:00 CET

*Terms are indicative and subject to change

BASKET COMPONENTS

Tracker Certificate on the US Biotech Basket

Underlying	Bloomberg Ticker	ISIN	Initial Level	Weight*
ALEXION PHARM	ALXN US Equity	US0153511094	USD 151.47	10%
ALNYLAM PHARMACE	ALNY US Equity	US02043Q1076	USD 67.68	10%
BIOGEN INC	BIIB US Equity	US09062X1037	USD 270.12	10%
BIOMARIN PHARMAC	BMRN US Equity	US09061G1013	USD 86.94	10%
CELGENE CORP	CELG US Equity	US1510201049	USD 105.75	10%
GILEAD SCIENCES	GILD US Equity	US3755581036	USD 97.15	10%
ILLUMINA INC	ILMN US Equity	US4523271090	USD 171.55	10%
PORTOLA PHARMACE	PTLA US Equity	US7370101088	USD 23.86	10%
REGENERON PHARM	REGN US Equity	US75886F1075	USD 406.65	10%
VERTEX PHARM	VRTX US Equity	US92532F1003	USD 83.59	10%


*on initial fixing date

Julius Bär

Structured Products

Bank Julius Baer & Co. Ltd.
Hohlstrasse 604/606
P.O. Box
CH-8010 Zurich
Switzerland

Telephone +41 (0) 58 888 81 81



IMPORTANT LEGAL DISCLAIMER

For distribution in Switzerland only. This presentation constitutes marketing material and is not the result of independent financial research. Therefore the legal requirements regarding the independence of financial research do not apply. The presentation is intended for information purposes only and does not constitute an offer, a recommendation or an invitation by, or on behalf of, Julius Baer to make any investments. The views expressed in this presentation may not reflect the official views of Julius Baer and may deviate from the opinion of other departments of the Bank or any other third party. The presentation was produced at the time of writing and is subject to change without notice. Services and/or products mentioned in this presentation may not be suitable for all recipients (i.e. retail clients). This presentation has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider the suitability of the transaction to individual circumstances and objectives. Any investment or trading or other decision should only be made by the client after a thorough reading of the relevant product term sheet, subscription agreement, information memorandum, prospectus or other offering document relating to the issue of the securities or other financial instruments. Nothing in this presentation constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate for individual circumstances. Julius Baer recommends that investors independently assess, with a professional advisor, the specific financial risks as well as legal, regulatory, credit, tax and accounting consequences. The price of financial instruments may vary and is exposed to general risks inherent in equities markets, currencies, interests as well as in political changes. Past performance is not a reliable indicator of future results and performance forecasts are not a reliable indicator of future performance. An investor may lose part or all of his investment. Although the information and data herein are obtained from sources believed to be reliable, no representation is made that the information is accurate or complete. Julius Baer does not accept liability for any loss arising from the use of this presentation.

Structured products (e.g. baskets, certificates) are complex financial products which involve a high degree of risk. They are intended exclusively for investors who have the knowledge and experience necessary to understand all risks and merits involved. Structured products are not comparable with conventional debts or equity securities and will not be covered by any financial compensation or insurance scheme. In particular, a structured product does not constitute a participation in a collective investment scheme. It constitutes a direct, unconditional, unsecured and unsubordinated obligation of the issuer. The product's value is not only dependent on the development of the underlying(s), but also on the credit-worthiness of the issuer. As structured products may be denominated in another currency than the one of the investor's home member state, fluctuations in exchange rates may adversely affect the market value of the product. Structured products were not registered with the local regulator and are not publicly distributable outside of Switzerland. Not all the risks and merits associated with structured products can be disclosed in this presentation. Therefore, potential investors should consult the entire product documentation related to the specific issuance before making any investment decision. The documentation can be obtained free of charge from your relationship manager or requested at derivatives@juliusbaer.com. Julius Baer makes no representation as to the suitability or appropriateness of the product for any particular investor.

NEITHER THIS PRESENTATION NOR ANY COPY THEREOF MAY BE SENT, TAKEN INTO OR DISTRIBUTED IN THE UNITED STATES OR TO ANY US PERSON AS DEFINED IN REGULATION S OF THE US SECURITIES ACT OF 1933.

© Julius Baer Group, 2016